Actively Recruiting
High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke (HRMRI-ICAS): a Prospective, Multicenter Cohort Study
Led by General Hospital of Shenyang Military Region · Updated on 2025-08-21
2110
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to establish a large-scale, multi-center database using high-resolution magnetic resonance imaging (HRMRI) to study intracranial atherosclerotic plaques in Chinese patients who have experienced ischemic stroke. Intracranial atherosclerotic disease is a leading cause of ischemic stroke, especially in Asia, and HRMRI provides a non-invasive, detailed way to assess arterial plaque characteristics, which are important for understanding stroke causes and prevention. The study involves collecting clinical data and using HRMRI to evaluate the morphology and composition of plaques in intracranial arteries. This imaging technique allows detailed analysis of plaque features such as lipid-rich cores, fiber cap thickness, hemorrhage, and calcification. Participants will be enrolled within two weeks of stroke onset and will undergo HRMRI to monitor their arterial plaques. Participants will be followed over time to assess stroke recurrence and other cardiovascular events at intervals of 90, 180, and 360 days. Functional independence and the relationship between plaque characteristics and cerebral small vessel disease will also be evaluated using clinical scales like the modified Rankin Scale. The study includes safety monitoring and data collection to understand the progression and outcomes of intracranial atherosclerosis in stroke patients.
CONDITIONS
Brief Title
High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient age 40 years or older
- Stroke onset within 2 weeks
- Baseline NIH Stroke Scale (NIHSS) score 16 or less
- Ischemic stroke confirmed by head CT or MRI
- Premorbid modified Rankin Scale (mRS) score 1 or less
- Extracranial artery stenosis on lesion side 50% or less
- Culprit or possible culprit plaque with 40% or more plaque burden on HRMRI in specific brain arteries
- Signed informed consent
You will not qualify if you...
- Intracranial hemorrhage detected by head CT
- Contraindication to MRI or inability to complete required MRI sequences
- Presence of intracranial tumor, arteriovenous malformation, or aneurysm
- Serious comorbid diseases with life expectancy less than one year
- Pregnancy
- Patients deemed unsuitable for the study by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 2 weeks after stroke onset
Participants undergo high-resolution magnetic resonance imaging (HRMRI) to assess intracranial atherosclerotic plaques and collect clinical data.
1 visit (in-person)
Duration - Up to 360 days
Participants are monitored for stroke recurrence and cardiovascular events, with assessments of functional independence over time.
Visits at 90 days, 180 days, and 360 days (in-person or remote)
Trial Site Locations
Total: 1 location
1
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016
Actively Recruiting
Research Team
H
HuiSheng
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here